Skip to main content

Table 1 Patient and disease characteristics

From: Unplanned hospitalizations in patients with locoregionally advanced head and neck cancer treated with (chemo)radiotherapy with and without prophylactic percutaneous endoscopic gastrostomy

Characteristic All patients (n = 310) pPEG
(n = 175)
nPEG or rPEG (n = 135) P value
Age at first diagnosis, years
 Median (range) 61 (20–94) 62 (20–83) 61 (40–94) ns
 ≤ 60, n (%) 139 (44) 75 (43) 64 (47) ns
 > 60– ≤ 70, n (%) 111 (36) 36 (37) 47 (35) ns
 > 70– ≤ 80, n (%) 45 (15) 32 (18) 13 (10) .035
 > 80, n (%) 15 (5) 4 (2) 11 (8) .029
Sex, n (%)
 Female 75 (24) 129 (74) 106 (79) ns
 Male 235 (76) 46 (26) 29 (21) ns
ECOG performance status, n (%)
 0 112 (36) 56 (32) 56 (43) ns
 1 153 (50) 87 (50) 66 (50) ns
 2/3 40 (14) 30 (18) 9 (7) .006
 Missing, n 5 1 4 na
 Median (range) baseline BMI, kg/m2 24.9 (16.8–38.7) 24.9 (16.8–38.6) 24.9 (17.6–36.8) ns
Body weight loss during RT, CTCAE grade, n (%)
 0 135 (47) 92 (55) 43 (36) .002
 1 87(30) 48 (29) 39 (33) ns
 2 62 (22) 26 (15) 36 (30) .004
 3 2 (1) 1 (1) 1 (1) ns
 Missing, n 24 8 16 na
Smoking habits
 Never smoker 34 (13) 21 (13) 13 (12) ns
 Ex-smoker 75 (29) 47 (30) 28 (26) ns
 Current smoker 153 (58) 87 (56) 66 (62) ns
 Missing, n 48 20 28 na
Tobacco use, pack-years
 Median (range) 40 (0–150) 40 (0–150) 40 (0–120) ns
 > 40 (i.e. above median), n (%) 100 (44) 65 (46) 35 (41) ns
 Missing, n 83 34 49 ns
Alcohol abuse, n (%)
 No 85 (33) 54 (35) 31 (31) ns
 In the past 23 (9) 15 (10) 8 (8) ns
 Yes 147 (58) 85 (55) 62 (61) ns
 Missing, n 55 21 34 na
Tumor localization, n (%)
 Oral cavity 63 (20) 36 (21) 27 (20) ns
 Oropharynx 149 (48) 77 (44) 72 (53) ns
 Hypopharynx 44 (14) 33 (19) 11 (8) .008
 Larynx 39 (13) 16 (9) 23 (17) ns
 Multi-compartemental 15 (5) 13 (7) 2 (2) .016
Tumor category, n (%)
 T1 25 (8) 9 (5) 16 (12) .036
 T2 95 (31) 42 (24) 53 (39) .004
 T3 102 (33) 59 (34) 43 (32) ns
 T4 88 (28) 65 (37) 23 (17) < .001
Nodal category, n (%)
 N0 36 (12) 17 (10) 19 (14) ns
 N1 55 (18) 21 (12) 34 (25) .004
 N2 206 (66) 128 (73) 77 (57) .003
 N3 11 (4) 9 (5) 5 (4) ns
UICC stage (7th edition), n (%)
 III 65 (21) 22 (13) 43 (32) < .001
 IVA 228 (74) 142 (81) 86 (64) < .001
 IVB 17 (5) 11 (6) 6 (4) ns
Surgical interventions, n (%)
 Primary oncologic resection 78 (25) 42 (27) 36 (27) ns
 Neck dissection 214 (69) 121 (69) 93 (69) ns
PEG tube placement, n (%)
 Prophylactic 175 (56) 175 (100) 0 (0) na
 Reactive 34 (11) 0 (0) 34 (25) na
 None 101 (33) 0 (0) 101 (75) na
Median (range) duration of PEG dependency, days 266 (4–2969) 274 (40–2969) 231 (4–2554) < .001
Chemotherapy, n (%)
 Concomitant 266 (86) 161 (92) 105 (78) < .001
 Neoadjuvant 33 (11) 21 (12) 12 (9) ns
  1. BMI body mass index, CTCAE Common Terminology Criteria for Adverse Events, na not applicable, ns not significant, nPEG no PEG, PEG percutaneous endoscopic gastrostomy, pPEG prophylactic PEG, rPEG reactive PEG, RT radiotherapy, UICC Union for International Cancer Control